mo:re reported that the FDA approved the first IND in oncology for which efficacy data were generated solely from human vascularized organoid-based combination studies in October 2025.
Published
Signal category
Research & Knowledge
Quote
“In October 2025, the FDA approved the first IND in oncology for which efficacy data were generated solely from human vascularized organoid-based combination studies.”
— mo:re team
Company
mo:re
3D Cell Culture - Automated, verified, standardized
- Industry
- Biotechnology Research
- Location
- Hamburg, DE
- Company size
- 14 employees
3D Cell Culture - automated, verified, standardised. At MO:RE, we empower life science researchers to generate reproducible, quality-controlled, and human-relevant 3D cell models (NAM) that accelerate drug discovery, reduce reliance on animals, and prepare R&D pipelines for regulatory approval. The MO:BOT is the first fully automated platform that standardizes NAM workflows from cell culture to drug screening with built-in quality control and regulatory-grade traceability. Every step from organoid generation to downstream assays is tracked, documented, and auditable, creating comprehensive data packages that support IND submissions and establish a foundation for GMP compliance. Unlike fragmented solutions, MO:BOT delivers an integrated system for producing, testing, and validating human-relevant models at scale.
Founded 2023